Visible Thrombolysis Acceleration of a Nanomachine Powered by Light-Driving F0F1-ATPase Motor by Xiaoxia Duan et al.
Duan et al. Nanoscale Research Letters  (2015) 10:227 
DOI 10.1186/s11671-015-0918-zNANO IDEA Open AccessVisible Thrombolysis Acceleration of a
Nanomachine Powered by Light-Driving
F0F1-ATPase Motor
Xiaoxia Duan1†, Lifeng Liu2,3†, Weijian Jiang2,4* and Jiachang Yue1*Abstract
We report on thrombolysis acceleration of a nanomachine powered by light-driving δ-subunit-free F0F1-ATPase
motor. It is composed of a mechanical device, locating device, energy storage device, and propeller. The rotory
δ-subunit-free F0F1-ATPase motor acts as a mechanical device, which was obtained by reconstructing an original
chromatophore extracted from Rhodospirillum rubrum. We found that the bioactivity of the F0F1-ATPase motor
improved greatly after reconstruction. The zeta potential of the nanomachine is about −23.4 mV. Cytotoxicity induced
by the nanomachine was measured using cell counting kit (CCK)-8 assay. The A549 cells incubated with different
fractional concentrations of the nanomachine within 48 h did not show obvious cytotoxicity. The locating device helps
the nanomachine bind to the thrombi. Energy was easily stored by exposing the nanomachine to 600-nm-wavelength
irradiation, which promoted activity of the motor. The rotation of the long propeller accelerated thrombolysis of a
blood clot in vitro in the presence of urokinase (UK). This result was based on visual inspection and confirmed by a
series of tests.
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Stroke remains a dangerous disease throughout the world
and more than 5.7 million people experience an ischemic
stroke each year [1]. Ischemic stroke is also the most com-
mon cause of permanent disability [2]. Due to an aging
population, the rate of ischemic stroke is increasing each year
[3]. Evidence-based medical therapies of acute ischemic
stroke mainly include intravenous tissue-type plasminogen
activator (tPA), intra-arterial thrombolysis, or interventional
techniques [4, 5]. Although the American Heart Association/
American Stroke Association (AHA/ASA) stroke guidelines
were recently updated to support the use of tPA in selecting
patients up to 4.5 h after symptom onset [6], many patients
cannot get to a hospital within this time window. In addition,
administration of systemic therapy increases the risk of* Correspondence: jiangweijian666@163.com; zkyyjc@163.com
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in any medium, provided the original work is pbleeding [7–9]. Intra-arterial thrombolysis has extended this
time window to 6 h after symptom onset [10], but for many
medical institutions, the development and popularization of
this complex multilateral cooperation technology is still re-
stricted because of poor patient awareness, intention, and
other reasons [11–13]. Blocked blood vessels can be opened
using interventional techniques, but it requires experienced
operators for successful implementation. Furthermore, indi-
vidual risk factors are unavoidable, which makes catheter
intervention an infeasible approach.
Reopening occlusive blood vessels safely and efficiently re-
mains a very challenging work in patients with acute ische-
mic stroke or coronary heart disease. Our study focused on
nanotechnology-assisted thrombolysis to explore a new dir-
ection in the field of thrombotic diseases research, such as
developing new drugs. Compared with traditional thrombo-
lytic methods, the nanotechnology devices are advanta-
geous; they combine the effects of biochemical enzymolysis
of a pure drug with the mechanical force of a nanodevice.
Active research is currently working on the development
and construction of nanobiomedical devices, which may
overcome the shortcomings of traditional therapy.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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is widely present in nature and has been discussed as a
micro-mixer in the past [14]. In this study, a δ-subunit-
free F0F1-ATPase motor was generated by reconstructing
the original chromatophore extracted from Rhodospiril-
lum rubrum as previously described [15]. The propeller
and thrombus-locating device were introduced by bio-
chemical reaction, and the nanomachine was subsequently
constructed successfully. Rotation of the propeller can ac-
celerate thrombolysis in a urokinase environment. More-
over, this nanomachine can work continuously due to
stored energy that can be replenished when the device is
exposed to light. In this study, the device induced an effi-
cient and accelerated thrombolytic process.
Methods
Chemical and Materials
The antibody against the β-subunit was prepared ac-
cording to a previous study [16] and purified according
to the study by Su et al. [17]. N-biotin, ATP, LDH,
NADH, and fibrinogen (F8630) were purchased from
Sigma (Sigma-Aldrich, St. Louis, MO, USA) as well as a
mouse monoclonal anti-fibrinogen antibody (Sigma-Aldrich,
St. Louis, MO, USA). The protein nanoparticle was
provided by Wuhan Institute of Virology, Chinese
Academy of Sciences. Lipid-biotin was purchased from
Avanti (Avanti Products, Doral, FL, USA). Fluorescein
isothiocyanate (FITC) was purchased from Molecular
Probes (Eugene, OR, USA). Human whole blood was
drawn from healthy volunteers by sterile venipuncture.
Informed written consent was obtained from all partici-
pants, and the protocol of the study was approved by the
Ethical Committee of the Capital Medical University.
Preparation of Blood Clots
Briefly, 2 ml of human peripheral blood was drawn from
healthy volunteers by sterile venipuncture and was injected
rapidly into a polypropylene tube (Shuanghe pharmaceut-
ical company, Beijing, China) with a length of 20 cm and
internal diameter 3 mm. This type of tube is biocompatible
and initiates coagulation easily. Both ends of the tube were
immediately clipped tightly and incubated at 37 °C over-
night in order to achieve maximal clot retraction and sta-
bility [18].
After the incubation, long cylindrical clots along the
inner diameter of approximately 2 mm were obtained
once they were pushed out of the tubes. The long clots
were cut into small pieces with a 2 mm width and diam-
eter at the time of the experiment.
Construction of Nanomachine
The nanomachine is composed of three parts: an energy
storage device, power device with a long propeller, andlocating device. The construction of this nanomachine
was initiated by removing the F1 from chromatophore.
Reconstruction of F0F1-ATPase Molecular Motor
The chromatophore containing F0F1-ATPase was pre-
pared as previously described [19]. It was incubated with
2 M LiCl, 0.1 mM Tricine-NaOH, 10 mM MgCl2, and
1 mM ATP for 20 min at 4 °C and then washed twice
with TSM buffer by centrifugation. This step removed
most of the F1 and clearly isolated the δ-subunit from F0.
Reconstruction was initiated by removing F1 from
chromatophore followed by grafting the alternative PS3
F1 (α3β3γ) onto it (Fig. 1). At the same time, ε-subunit
was complemented into the reconstruction system. The
PS3 F1 (α3β3γ) and the ε-subunit were prepared based
on previously described methods [17, 20–22]. Next, 5 μg
of chromatophores lacking F1, 10.4 μg ε-subunit, and
50 μg purified F1 (α3β3γ) were incubated at 25 °C for
12 h in reconstitution buffer containing 50 mM Tricine-
NaOH (pH 8.0), 4 mM ATP, 25 mM MgCl2, 1 mM di-
thiothreitol, and 10 % glycerol. The retained system was
centrifuged at 180,000 g for 30 min. The precipitate was
resuspended in buffer (containing 50 mM Tricine-
NaOH, pH 8.0, 10 % glycerol, and 25 mM MgCl2) and
washed three times with the same buffer followed by
centrifugation after each step. An artificial δ-subunit-
free F0F1-ATPase within chromatophore was successfully
reconstructed. A schematic diagram of the reconstruc-
tion process is shown in Fig. 1.
Installing Propeller for Nanomachine
The propeller of the molecular motor was an anti-β-
subunit polyclonal antibody-N-biotin-avidin-N-biotin-
protein nanoparticle. To construct this propeller, 44.2 μl
of 17 μM anti-β-subunit antibody and 3.8 μl of 1 mM
N-biotin were incubated for 1 h, which formed the
antibody-N-biotin complex. Then, 147 μl of 29 μM
avidin was added and incubated at room temperature for
5 min, followed by incubation with 8.5 μl of 350 μg/ml
protein nanoparticle and 1.5 μl of 1 mM N-biotin at room
temperature for 1 h. Next, 48 μl [(polyclonal antibody
against the β subunit)-N-biotin-avidin] and 10 μl N-
biotin-protein nanoparticle were added and incubated
at room temperature for 5 min. These steps resulted in
the connection of [(polyclonal antibody for the β subunit)-
N-biotin-avidin-N-biotin-protein nanoparticle] through
long, whole links to the molecular motor. The final nano-
machine can produce a stronger stirring force compared
with the molecular motor alone due to the long propeller.
Installation of the Locating Device
Briefly, 400 μl of 0.5 μg/μl chromatophores and 3.2 μl of
5.5 mM lipid-biotin were incubated at 4 °C for 25 min.
Then, 632 μl of 29 μM avidin was added and incubated
Fig. 1 Reconstruction procedures for the δ-subunit-free F0F1-ATPase molecular motor. a The original holoenzyme ATPase molecular motor.
b Subunit-free chromatophore. c The δ-free F0F1-ATPase molecular motor. The δ-subunit and most of the other subunits were removed from the
original holoenzyme ATPase molecular motor (chromatophore) in LiCl solution and B was attained. The alternative PS3 F1 (α3β3γ) was added into
the reconstruction system and ε-subunit was complemented at the same time, thus generating the δ-free F0F1-ATPase molecular motor
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chromatophore-lipid-biotin-avidin complex. Subsequently,
210.1 μl of 17 μM anti-fibrinogen antibody and 17.9 μl of
1 mM N-biotin were incubated at room temperature for
1 h, N-biotin-anti-fibrinogen antibody complex formed.
Finally, 1035.2 μl of the chromatophore-lipid-biotin-avidin
complex and 228 μl of the N-biotin-anti-fibrinogen anti-
body were mixed and incubated at room temperature for
5 min. The anti-fibrinogen antibody easily reacts with the
fibrinogen in the thrombi and works as a locating device.
Assembling Nanomachine
For assembly, 26 μl of anti-β subunit polyclonal antibody-
N-biotin-avidin-N-biotin-protein nanoparticle complex was
mixed with 1263.2 μl of molecular motor-lipid-biotin-
avidin-N-biotin-anti-fibrinogen antibody complex and
incubated at room temperature for 5 min followed by
centrifugation at 35,000 rpm (180,000 g) for 30 min.
The precipitate was finally resuspended in light-irradiation
buffer [10 mM Tricine-NaOH (pH = 8), 2 mM MgCl2,
and 50 mM KCl].
Measurement of Bioactivity of the Reconstructed δ-Free
F0F1-ATPase
The hydrolysis activity of the holoenzyme and the recon-
structed molecular motor was measured according to
previously described methods [17, 23]. In general, the ef-
ficiency of the reconstructed molecular motor was deter-
mined by the percentage of ATP hydrolysis. The rate of
ATP hydrolysis was measured by the disappearance of
NADH. Measuring the fluorescence intensity of NADH
at 340 nm can indirectly reflect the activity of a hydro-
lytic enzyme because the maximum absorption peak of
NADH is 340 nm. Fluorescence intensity was measuredat 37 °C using a UV-2101PC Shimadzu Spectrophotometer
(Shimadzu Corp., Tokyo, Japan).
The Size Distribution and Zeta Potential
The size distribution and zeta potential were examined
by Zetasizer Nano-ZS (Malvern Instruments Ltd.,
Worcestershire, UK). The analysis software was Zetasizer
software version 7.02 supplied by the manufacturer
(Malvern Instruments Ltd., Worcestershire, UK). The
samples were diluted 30-fold in water. Dynamic light
scattering (DLS) was measured at 25 °C using a helium–
neon laser at the wavelength of 633 nm, detection angle of
173°.
Cytotoxicity of the Nanomachine
The cytotoxicity of the nanomachine was assessed by
cell counting kit (CCK)-8 assay (Beyotime, Beijing,
China). The A549 cells were seeded onto the 96-well
plate at a density of 5000 cells per well in 100 uL
medium. The nanomachine solutions were lighted half
an hour by the ultraviolet rays for sterilization and then
diluted with fresh media to obtain different fractional
concentrations—i.e., nondiluted (100 %) and diluted (1:7
[12.5 %], 1:3 [25 %], 1:1 [50 %]) extract solutions with
Dulbecco’s Modified Eagle’s Medium (DMEM), respect-
ively. Ten microliters of CCK-8 reagents were added
into each well, and the plate was left standing for an
additional 2 h at 37 °C. The optical density (OD) was
measured using a multifunctional microplate reader
(SpectraMax M5, Molecular Devices, Sunnyvale, CA,
USA) at 450 nm wavelength. This process was repeated
eight times in parallel. The results are expressed as the
relative cell viability (%) with respect to a blank group
only with a culture medium.
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Urokinase solutions were prepared in the morning and
stored at 4 °C until being used on the experiment day.
Briefly, 250,000 units urokinase powder (Lizhu Pharma-
ceutical Factory, Guangzhou, China) was dissolved in
2 ml 0.9 % sterile saline, and the stock solution of 125
U/μl urokinase solution was made. Then, 1 ml of stock
was diluted with 1 ml of saline to 62.5 U/μl urokinase
solution, and 1 ml of 62.5 U/μl urokinase solution was
diluted with 1 ml of saline to 31.25 U/μl urokinase solu-
tion. Using the same method, we obtained the final con-
centration of 15.625 U/μl solution. We then prepared
final concentrations of 62.5, 31.25, and 15.625 U/μl uro-
kinase solutions by making dilutions of the stock. Thus,
80 μl of the above dilutions was equivalent to 5000,
2500, and 1250 U of urokinase, respectively.
Detection of D-Dimer
The D-dimer level of all samples was detected with an
ACL TOP automatic coagulation analyzer (Beckman
Coulter, Inc., AmericaBrea, CA, USA) using latex immu-
noturbidimetry. Each sample was assayed three times.
Data Analysis
The data are presented as means ± standard deviation.
All experimental data were the average of at least eight
independent tests. All data were processed by SPSS (ver-
sion 19.0; IBM, USA) software. The least significant dif-
ference (LSD) at the 5 % confidence level was used for
comparing treatments.
Results and Discussion
The Hydrolysis Activity of the Reconstituted δ-Free
FoF1-ATPase
When the chromatophore was incubated with LiCl, δ-
subunit separated from b2-subunits of F0 and most of
the F1 was removed from the c-ring rotor of F0. After
the system was centrifuged three times, the remained
protein and LiCl were removed. When the PS3 F1 puri-
fied from thermophilic bacteria Bacillas and the ε-
subunit purified from Escherichia coli were added into
the above resuspended system, the ATP synthase cata-
lytic complex was assembled back to the F0 inset in the
membrane of the chromatophore. The only difference
was that the δ-subunit was not connected to the b2 and
the rotation of F1 was no longer restricted by b2. As a re-
sult, the F1 motor rotated more easily.
The curve in Fig. 2a indicates the disappearance of
NADH and reflects the ATP hydrolysis rate of the two
different systems. As shown in Fig. 2a, the reconstructed
motor had better hydrolysis activity than the holoen-
zyme based on the usage of NADH and the ATP hy-
drolysis rate. This improvement in bioactivity provided a
good foundation for the next step experiment.Installation of Propeller and Locating Device
This motor may generate stronger stirring power if a
long chain is added to the β- or α-subunits. Therefore,
we linked an anti-β-subunit biotinylated antibody to the
β-subunit and then introduced avidin for binding to the
biotin. Using this approach, a propeller with a greater
length was bound to the molecular motor (Fig. 2b).
The vesicle wall of the chromatophore is composed of
a lipid bilayer membrane. When lipid-biotin is mixed
with the chromatophore, the lipid inserts into the mem-
brane with the linked biotin extending outside the mem-
brane (Fig. 2b). This method allows for binding of the
anti-fibrinogen antibody containing avidin to the biotin
on the chromatophore. This anti-fibrinogen antibody
and the fibrinogen in blood clots can form a complex of
antigen-antibody, which helps the nanomachine to bind
to the thrombi and accelerates thrombolysis.
Diameter and Zeta Potential
Table 1 shows the size distribution and zeta potential of
the chromotophore and the nanomachine. The size of
the nanomachine is about 110 nm (Additional file 1:
Figure S1). It is a little bigger than chromatophore’s be-
cause of the avidin–biotin complex assembling on the
surface layer of it. According to this study [24], the
diameter of the avidin–biotin complex is about 5–
10 nm, which is consistent with our results. As shown
in Table 1 and Additional file 2: Figure S2, the zeta po-
tential of the nanomachine measured in pH 7.4 water
solution is about −23.4 mV, which was considered rela-
tively stable [25].
Cell Viability of the Nanomachine
The cell viability of the nanomachine was evaluated
using the CCK-8 assay which has a higher sensitivity and
a better reproducibility than traditional MTT assay. As
shown in Fig. 3, there is almost no cytotoxicity at various
concentrations of the nanomachine and above 85 % of
cells remained alive in 48 h. In addition, close to or
more than 90 % of cells remained alive when incubated
with the nondiluted (100 %) nanomachine solutions
throughout the test, which means the nanomachine has
no obvious cytotoxicity and has a good biocompatibility.
Energy Storage in the Nanomachine
NaN3 and ATP were added to the nanomachine at a
final density of 5 and 2 mM, respectively. Then, 40 μl of
this nanomachine solution was irradiated with 600-nm
light-emitting diode (LED) with a 560-nm filter for
40 min at 4 °C. NaN3 and ATP can fix the relative rota-
tion of γ and α3β3 and form a new and combined rotor
α3β3γεcn which rotates more freely as a whole. The mo-
lecular motor began to rotate in one direction as protons
transported from the outside of the chromatophores into
Fig. 2 The hydrolysis activity of the native molecular motor and structure of the constructed nanomachine. a The hydrolysis activity of the native
molecular motor compared to the reconstructed molecular motor. The horizontal axis shows time, and the vertical axis shows the fluorescence
intensity, which is proportional to the concentration of NADH. The square matches the native F0F1-ATPase molecular motor, and the circle matches the
reconstructed δ-free F0F1-ATPase molecular motor. b Structure of the constructed nanomachine. The nanomachine consists of four parts: rotary motor,
energy storage device used for energy transformation and storage, locating device for combining fibrin present in the thrombi, and a propeller for
accelerating thrombolysis. Light irradiation can stimulate the photosynthesis center to store energy in the nanomachine. The long propeller produced
the stronger mixing power. The anti-fibrinogen antibody (locating device) can recognize and bind to fibrin within the thrombi
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established. The motor began to rotate in the reverse
direction when the irradiation was removed and the
temperature reached room temperature. The contrasting
movements resulting from energy storage and release








Chromatophore 99.89 0.192 −20.2
Nanomachine 110.2 0.251 −23.4In Vitro Acceleration of the Nanomachine in Urokinase-
Mediated Thrombolysis
Figure 4a provides a schematic diagram of the experi-
mental process. The bar thrombus was cut into equal
sections and washed with normal saline three times. The
sections were then placed in individual wells of a 96-well
plate, and 10 μl nanomachine solution was carefully
placed on the surface of each thrombus ensuring full
contact and isopyknic 0.9 % sterile saline was added in
control groups. Then, 80 μl urokinase was added into
the well and incubated for 1.5 h at room temperature.
Each thrombus was found resolved slowly during the in-
cubation time. At the end of the incubation, all of the
Fig. 3 Cell viability of the nanomachine by CCK-8 assay with different concentrations of extract solutions
Fig. 4 Flow chart of thrombolysis process and relative level of
thrombolysis. a A flow chart of thrombolysis process. 1 A blood clot
was placed in a well of a 96-well plate; 2 the nanomachine was
added directly onto the blood clot and the locating device reacted
with the blood clot; 3 urokinase (80 μl) was added into the well; 4
thrombolysis; 5 residual blood clot; 6 liquid mixture after thrombolysis;
7 liquid supernatant after centrifugation for 5 min at 1500 rpm; and
8 liquid supernatant without the nanomachine after centrifugation
for 30 min at 35,000 rpm. b The relative level of thrombolysis.
Group A with nanomachine and group B without nanomachine
(control group). The liquid mixture in chart was centrifuged
at 1500 rpm
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injected into Eppendorf (EP) tubes. The composition of
the liquid contains degradation products of fibrin and
red blood cell fragments.
We then centrifuged all tubes at 1500 rpm and 4 °C
for 5 min. Through this approach, the fragments of
thrombolysis that had been dissolved sank to the bottom
of the tube, while the nanomachine remained suspended
in the solution. The results were shown in Fig. 4b. Series
A samples were nanomachine groups while the series B
were control groups. For A1, A2, and A3, the concentra-
tion of urokinase was 1250, 2500, and 5000 U, respect-
ively. Series B had the same concentrations orderly.
Series A samples had three layers and the nanomachines
settled in the middle. Series B had only two layers:
supernatant and precipitate. The volume of precipitate
can reflect the extent the blood clots were dissolved,
which suggests that the larger volume of the bottom
sediments is, the more thrombolysis of the clots have.
Based on visual inspection, we found that A>B, A1>B1,
and A2>B2, which demonstrates that the nanomachine
facilitates thrombolysis of clots by effectively stirring in
the urokinase solution of different concentrations.
We performed further quantification to confirm the
above results, whereby 25 μl supernatant aspirated from
the above EP tubes were diluted with the same volume
physiological saline and then centrifuged at 3000 rpm
for 15 min. The D-dimer in the supernatant was then
assessed by the automatic coagulation analyzer. Table 2
shows the group assignment and detailed results of the
D-dimer. The test was repeated eight times and pre-
sented as the average values of each subgroup (Fig. 5a).
The D-dimer is the specific biomarker in terminal deg-
radation products of cross-linked fibrin, which is the
Table 2 The concentration of D-dimer in different subgroups
(mg/L)
Concentration of urokinase (U) Nanomachine group Control group
1250 4.25 ± 0.53* 2.83 ± 0.67
2500 8.61 ± 0.57* 6.80 ± 1.02
5000 13.89 ± 1.43* 11.3 ± 1.06
The levels of D-dimer in all of the nanomachine subgroups were higher than
the control groups
*P <0.05 compared with the control group
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ase. The D-dimer level increases as the cross-linked fi-
brin degradation of the clot increases, and the changes
of plasma D-dimer content has already been recognized
as the symbol of thrombolysis [26]. Lawler et al. found
that if the thrombolysis effect was reached, the D-dimer
level increased rapidly. Thus, plasma D-dimer level canFig. 5 The concentration of D-dimer, fluorescence intensity of thrombolysis, an
of D-dimer in the supernatant of each subgroup. Data are shown as mea
groups and B series are control groups. *P <0.05 compared with the cont
supernatant after the system were centrifuged for 30 min at 35,000 rpm.
the nanomachine and B series contains the control groups. *P <0.05 com
the supernatant after thrombolysis assisted by 0, 5, 10, and 20 μl nanomabe used as an important observation index in treatment
effectiveness of thrombolysis [27]. Therefore, we can
quantitate the degree of thrombolysis by measuring the
D-dimer level in the solution. As shown in Fig. 5a, the
levels of D-dimer in all of the nanomachine subgroups
were higher than the urokinase alone groups, illustrating
that the nanomachine accelerates the lysis of clots at dif-
ferent urokinase concentrations.
In order to confirm these results, we tested the nano-
machine effectiveness with FITC-labeled thrombus using
another semi-quantitative method. Ectogenic fibrinogen
labeled by FITC was mixed with whole blood obtained
from healthy volunteers and the thrombus with fluores-
cence was made as described above. The experimental
procedure followed that outlined in Fig. 4a until step 6,
at which point the dissolved solution was placed at 4 °C
and centrifuged at 35,000 rpm for 30 min. Duringd fluorescence microscope images of the supernatant. a The concentration
n + standard deviation. All A series of samples are nanomachine
rol groups. b The fluorescence intensity of thrombolysis in the
Data are shown as mean + standard deviation. The A series contains
pared with the control groups. c Fluorescence microscope images of
chines
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nanomachines precipitated, and the material labeled by
FITC stayed in the supernatant. Therefore, the FITC-
labeled fibrin, which had been uniformly dispersed in
the buffer after nanomachine-mediated thrombolysis,
was measured by separating the supernatant from the
red blood cells and nanomachines through centrifuga-
tion. It is possible to assess the effects of increasing
thrombolysis by the nanomachine by comparing the
fluorescence intensities between groups. The stronger
the fluorescence intensity is, the more obvious the effect
of thrombolysis will be. Figure 5b shows the comparison
of fluorescence intensities between the nanomachine
groups and the control groups, whereby 10 μl suction
from the supernatant was spotted and assayed by a
fluorescence detector using a 480-nm-wavelength diode
as the excitation source. The mean values are shown in
Fig. 5b and Table 3. We found that the fluorescence in-
tensities of supernatants increased as the urokinase con-
centration increased and that the nanomachine groups
had higher fluorescence than the control groups
(A2>B2, A1>B1, and A>B, respectively). Taken together,
these findings confirmed that the nanomachine acceler-
ated the thrombolysis at different concentrations of
urokinase.
Figure 5c shows the results of thrombolysis of urokin-
ase incubated with increasing amounts of nanomachines
by fluorescence microscopy. To determine whether the
thrombolytic effect was strengthened by the nanoma-
chines, we added an increasing amount of nanomachines
(0, 5, 10, or 20 μl) to the system of 1250 U urokinase
and the same volume of FITC-labeled thrombus. After
the thrombolysis, 35,000 rpm centrifugation was con-
ducted and 5 μl of supernatant was spotted on an asep-
tic glass plate. As shown in Fig. 5c, white spots represent
lytic thrombus fragments. The brightness, number, and
diameter of these spots were compared visually under a
high-power fluorescence microscopy. We found that the
nanomachines increased the rate of thrombolysis of
urokinase in a concentration-dependent manner, as indi-
cated by a greater number of blood block fragments and
fluorescence intensity.
In the previous studies about assisted thrombolysis,
the researchers had used a variety of methods to try toTable 3 The values of fluorescence intensities in different
subgroups
Concentration of urokinase (U) Nanomachine group Control group
1250 37.6 ± 4.6* 18.3 ± 3.8
2500 63.0 ± 11.7* 42.3 ± 9.0
5000 87.0 ± 7.8* 59.7 ± 8.5
The nanomachine groups had higher fluorescence intensities than the
control groups
*P <0.05 compared with the control groupcarry the encapsuled drugs to reach the thrombus site,
such as liposomes and magnetic nanoparticles (NPs).
But as described in some reports, the use of liposomes
was limited by poor repeatability and low encapsulation
efficiency and enzyme inactivity, while magnetic NPs was
limited by sizes and complicated controllability [28–30].
In this work, we used F0F1-ATPase as a mechanical ro-
tation motor. We separated all the subunits from it first,
then reassembled and optimized, and obtained a new
relatively complicated nanomachine at last. Under the
condition of light driving, the new nanomachine can
produce proton gradient, which provides energy for the
nanomachine, and makes it rotate smoothly and easily
without the limitation of the δ-subunit. Although the
assembled process of the δ-subunit-free F0F1-ATPase is
relatively complicated, it has good repeatability, stability,
and activity according to our previous studies [14, 15, 22].
However, the proton gradient formed by the light driving
may be not the only selection. Li et al. entrapped glucose
oxidases (GODs) into the cavity of polymeric hollow
spheres of biomimetic nanocapsules, which can hydrolyze
glucose in the suspension and produce proton gradient,
thus supply power for ATPase. In comparison to our
light-driven proton pump, this type of biomimetic capsule
for ATP synthesis maybe a cheaper and better choice for
the future study [31].
The application of nanotechnology to assisted thromb-
olysis has been a research hotspot in the field of thromb-
olysis. In this experiment, the reassembled nanomachine
showed preferable assisted thrombolysis effect. It is
known that δ-subunit plays a switch role between the F0
and F1 in the ATPase and restricts the efficient rotation
of F1. The δ-subunit-free F0F1-ATPase could create pro-
ton potential energy under 4 °C continuous irradiation.
The proton gradient is an important basis to ensure F1 to
rotate as the rotor efficiently. The propeller device amplifies
the mechanical force like an extended mechanical arm and
results in a stirring effect in the process of thrombolysis,
which can make full contact between urokinase and throm-
bosis, and increase urokinase solution infiltrating into
thrombus, thus accelerates the process of thrombolysis.
Many problems such as biological toxicity and im-
mune reaction should be taken into account in the ap-
plication of nanotechnology in medicine. In this study,
the materials and buffer used to assemble nanomachine
were simulated in physiological environment of human
body. The cell viability evaluated using CCK-8 assay
shows that the nanomachine almost has no cytotoxicity
at various concentrations, assuring its good biocompati-
bility. Thus, we could have a try to use this nanoma-
chine in animal thrombolytic test in the future. In
animal experiments, the researchers tried to improve the
assembly technique, develop intelligent drug delivery
system, fabricate nanotechnology-based products, make
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degradable materials to encapsulate the drugs; all these
works were efforts to reduce adverse reactions [32–35].
In the future studies, in order to avoid the above compli-
cated restrictions and unpredictable results, we plan to
use electrodeposition coating technology [36] to fix the
assembled nanomachine to the tip of arterial catheter
during the interventional operation to help recanaliza-
tion in carotid artery occlusion model in New Zealand
rabbits. Even for animal experiment the nanomachine
could not be retained in vivo, thus, we could avoid the
biological toxicity and immune reaction and other ad-
verse effects which could not be detected at present as
far as possible.
Although there are many exciting developments in the
fields of nanotechnology and nanomedicine, they are still
in the early stages. It is envisaged that developments in
nanotechnology will have an enormous impact on the
field of thrombotic diseases. Much of the ongoing work
should be done in the future studies.
Conclusions
A δ-subunit-free F0F1-ATPase motor was successfully
created by reconstructing the original chromatophore
extracted from R. rubrum. Energy was stored when the
motor was exposed to 600-nm-wavelength irradiation at
4 °C and released when irradiation removed and
followed by a slow rise to room temperature. Both the
energy storage and release process promoted the rota-
tion of the nanomachine. The new combined propeller
and the thrombus-locating device in the motor formed a
more complicated nanomachine which has a good stabil-
ity and no cytotoxicity. This new nanomachine had bet-
ter thrombolysis effect than free urokinase.
Though additional studies are required to determine
the best way to optimize the reconstruction to get a
good biocompatible nanomachine which can be ob-
served in vivo, the new nanomachine which using less
thrombolytic drugs but getting more efficient thromb-
olysis brings us a promising research idea in the field of
thrombolysis study.
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